Dermatitis

Delgocitinib ointment was associated with improved efficacy over placebo in pediatric patients with moderate atopic dermatitis through 56 weeks of follow-up, according to a study.

Weekly dupilumab showed long-term safety and efficacy in atopic dermatitis patients in an open-label extension study presented at the EADV Congress virtual meeting.

Spongiotic dermatitis was the most commonly reported cutaneous reaction to COVID-19 vaccination among patients who also had biopsy results available for review, according to a registry-based study.

Dupilumab led to significant improvements in self-reported sleep disturbance among patients with atopic dermatitis, according to study results presented during the European Academy of Allergy and Clinical Immunology Hybrid Congress.

Sleep disturbance appeared common among school-aged children with atopic dermatitis and may be associated with neuropsychiatric impairment, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Certain probiotic strains lowered the risk for developing atopic dermatitis when administered to pregnant women and infants, according to a systematic meta-analysis published in Pediatric Allergy and Immunology.

Pediatric patients with atopic dermatitis who were treated with dupilumab and topical corticosteroids experienced an improvement in both itch and excoriations, according to a study presentation.

Abrocitinib combined with a medicated topical therapy was effective, well tolerated and improved quality of life in adolescents with atopic dermatitis, according to phase 3 results from the JADE TEEN Study.

The effect of the COVID-19 pandemic has been felt in every aspect of life in 2020, and that includes the dermatology world.

The FDA approved drugs and products for many dermatological diseases and conditions in 2020. Here are some of the top-read articles on Healio regarding this year’s dermatology FDA approvals.